Seres quietly discloses it has once again altered plans in ulcerative colitis
A month after another setback in its plans to treat ulcerative colitis, Seres Therapeutics quietly disclosed it will not move forward with a Phase Ib trial.
The move, disclosed in an SEC filing Wednesday, puts Seres in a predicament as the Cambridge, MA biotech failed with one potential UC drug, SER-287, last July, and again with another experimental drug last month.
That second attempt, with SER-301, was safe to proceed to the placebo-controlled second cohort in a Phase Ib trial even though outcome data from the 15 patients indicated none of them had achieved clinical remission after 10 weeks of treatment, Seres said on March 1.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.